Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.

Biopsy Cervical cancer Sentinel lymph node Ultrastaging

Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
27 Jun 2024
Historique:
received: 22 02 2024
revised: 15 06 2024
accepted: 23 06 2024
medline: 29 6 2024
pubmed: 29 6 2024
entrez: 28 6 2024
Statut: aheadofprint

Résumé

To report the outcome of SLN staging in the SENTIX international prospective trial of SLN biopsy in patients with cervical cancer with an intensive ultrastaging protocol and central quality control and to evaluate how the intensity of pathological assessment correlates with metastatic detection rate in SLNs. Eligible were patients with stages T1a1/LVSI+ to T1b2 (<4 cm, ≤2 cm for fertility sparing), common tumor types, no suspicious lymph nodes on imaging, and bilateral SLN detection. SLNs were examined intraoperatively and processed by an intensive protocol for ultrastaging (paraffin blocks sectioned completely in 150-μm intervals/levels). SLNs from each site were submitted for central quality control. In the SENTIX SLN study, 647 out of 733 enrolled patients underwent SLN ultrastaging, identifying 12.5% (81/647) with node positive, N1 cases. Intraoperative detection revealed metastases in 56.8% (46/81) of these cases, categorized into macrometastases (83.7%), micrometastases (26.3%), and isolated tumor cells (9.1%). Ultrastaging identified additional metastatic involvement in 43.2% (35/81) of patients, with detailed sectioning revealing metastases (MAC/MIC) at first level in 20 cases (24.7%), at levels 2-4 in 9 cases (11.1%), and at level ≥5 in 6 cases (7.4%). SLN ultrastaging detects additional 43% of N1 (MAC/MIC) in patients with negative LNs by imaging and intraoperative pathological assessment. The detection rate of positive SLN correlates with the intensity (number of levels) of ultrastaging. Examination of four levels from paraffin blocks, which detects >90% of patients with N1, is a reasonable compromise for an international standard for ultrastaging. NCT02494063 (ClinicalTrials.gov).

Identifiants

pubmed: 38941963
pii: S0090-8258(24)00330-5
doi: 10.1016/j.ygyno.2024.06.015
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02494063']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-89

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no conflict of interest.

Auteurs

Roman Kocian (R)

Gynecologic Oncology Center, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address: Roman.Kocian@vfn.cz.

Christhardt Kohler (C)

Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, Hamburg, Germany.

Sylva Bajsova (S)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava, Poruba, Czech Republic.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Ignacio Zapardiel (I)

Department of Obstetrics and Gynecology, La Paz University Hospital, Madrid, Spain.

Giampaolo Di Martino (G)

Gynecologic Oncology Surgical Division, Humanitas San Pio X, Milan, 20159, Italy; Gynecology Unit, IRCCS Fondazione San Gerardo dei Tintori, 20900, Monza, Italy.

Luc van Lonkhuijzen (L)

Center for Gynecologic Oncology, Academic Medical Centre, Amsterdam, Netherlands.

Borek Sehnal (B)

Department of Obstetrics and Gynecology, University Hospital Bulovka, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Octavio Arencibia Sanchez (OA)

Department of Gynecologic Oncology, University Hospital of the Canary Islands, Las Palmas de Gran Canaria, Spain.

Blanca Gil-Ibanez (B)

Unit of Gynecological Oncology, Institute Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, Barcelona, Spain.

Fabio Martinelli (F)

Department of Gynecological Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy; Gynecologic Oncology Surgical Division, Humanitas San Pio X, Milan, 20159, Italy.

Jiri Presl (J)

Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.

Lubos Minar (L)

Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Radovan Pilka (R)

Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic.

Peter Kascak (P)

Department of Obstetrics and Gynecology, Faculty Hospital Trencin, Trencin, Slovakia.

Pavel Havelka (P)

Department of Obstetrics and Gynecology, KNTB a.s, Zlin, Czech Republic.

Martin Michal (M)

Department of Obstetrics and Gynaecology, Hospital Ceske Budejovice, JSC, Ceske Budejovice, Czech Republic.

Toon van Gorp (T)

Department of Gynecology and Obstetrics, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium.

Kristyna Nemejcova (K)

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Pavel Dundr (P)

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

David Cibula (D)

Gynecologic Oncology Center, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.

Classifications MeSH